Sun Pharma gets CDSCO Panel nod to manufacture, market Progesterone SR Tablet

Published On 2022-10-11 12:30 GMT   |   Update On 2022-10-11 12:30 GMT
Advertisement

New Delhi: The drug major Sun Pharma has got green signal from the Subject Expert Committee (SEC) functional under Central Drug Standard Control Organization (CDSCO) to manufacture and market the Progesterone Sustained Release (SR) Tablets (200/300/400mg).

This came after the firm presented their proposal along with the bioavailability (BE) study report of Progesterone Sustained Release tablet 400mg before the committee.
Advertisement

Sustained Release (SR) Tablets are designed to release a drug in the body slowly over an extended period of time. It allows delivery of a specific drug at a programmed rate that leads to drug delivery for a prolonged period of time.

Progesterone is a hormone used for a variety of functions, including contraception, control of abnormal uterine bleeding, maintenance of pregnancy, and prevention of endometrial hyperplasia.

Progesterone binds and activates its nuclear receptor, PR, which plays an important part in the signaling of stimuli that maintain the endometrium during its preparation for pregnancy. Progesterone may prevent pregnancy by changing the consistency of cervical mucus to be unfavorable for sperm penetration, and by inhibiting follicle-stimulating hormone (FSH), which normally causes ovulation.

Exogenous progesterone supplementation is given for treatment of secondary amenorrhea, dysfunctional uterine bleeding, and endometriosis, for management of luteal phase deficiency, for preventing preterm delivery and also to prevent endometrial hyperplasia.

At the recent SEC meeting for Reproductive and Urology held on September 28th,2022 the expert panel reviewed the proposal and the bioavailability (BE) study report of Progesterone SR Tablet 400mg presented by the drug major Sun Pharma.
After detailed deliberation, the committee recommended the grant of permission to manufacture and market the applied drug products for an already approved indication.
Tags:    

Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.

NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.

Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .

Similar News